Medical Crossfire®: Navigating Treatment Decisions in mCRC: Sequencing Through Multiple Lines of Care

Medical Crossfire®: Navigating Treatment Decisions in mCRC: Sequencing Through Multiple Lines of Care is organized by Physicians' Education Resource, LLC (PER) and will be held from Mar 26, 2019 - Mar 26, 2020.

Target Audience:
This educational program is directed toward medical oncologists, gastroenterologists, gastrointestinal oncologists, and surgical oncologists who treat patients with CRC. Other healthcare professionals who have an interest in the treatment of CRC, such as nurses, physician assistants, fellows, and residents, are also invited to participate.

Accreditation:
• CME: 1.5

Activity Overview:
This Medical Crossfire® activity describes the latest advances in the treatment of metastatic colorectal cancer (mCRC). Panelists discuss all relevant aspects of diagnosis, treatment, molecular testing, clinical trial data, and appropriate methods for adverse event management. This activity also examines the place of targeted and immunotherapeutic treatments in current clinical use, as well as treatments in clinical development.

Learning Objectives:
After completion of this activity, you should be better prepared to:
• Discuss the use of novel biomarkers and key testing technologies that can inform clinical decision making among patients with mCRC
• Delineate the appropriate application of current guidelines and standards of care in patients with mCRC previously-treated with targeted, chemotherapeutic, and immunotherapeutic options
• Examine new investigational clinical trial evidence, as well as key ongoing studies, of targeted treatments and their potential to impact management strategies in CRC treatment settings
• Describe how common and uncommon adverse events can be proactively mitigated and managed for patients undergoing treatment for CRC

Benefits of Participation:
• Develop an appreciation of the targeted treatment options available in the management of mCRC
• Recognize targetable mutations in mCRC and considerations in molecular testing
• Contextualize clinical trial data in specific patient scenarios, including in patients with specific phenotypic and molecular features
• Optimize management of potential adverse events with immunotherapeutic and targeted therapies used in the management of mCRC

Additional details will be posted as soon as they are available.